Highlights
- Non-White patients admitted with heart failure in England demonstrate significantly lower mortality rates compared to White patients after adjusting for age, sex, and comorbidities.
- The study found that ethnic minority groups often receive superior guideline-directed medical therapy (GDMT) upon hospital discharge, particularly for heart failure with reduced ejection fraction (HFrEF).
- The findings suggest that a universal healthcare system (NHS) can provide a framework where specialist care helps narrow or even reverse traditional ethnic disparities in cardiovascular outcomes.
Background: The Paradox of Ethnicity and Cardiovascular Outcomes
For decades, clinical literature—predominantly from the United States—has highlighted significant racial and ethnic disparities in cardiovascular health. Historically, minority populations have often faced higher rates of hypertension, diabetes, and subsequent heart failure (HF), frequently coupled with poorer access to high-quality care and worse clinical outcomes. However, the impact of ethnicity on heart failure outcomes within the context of a universal health system, such as the United Kingdom’s National Health Service (NHS), remains a subject of intense investigation.
The COVID-19 pandemic further complicated this landscape, as initial data suggested that ethnic minorities were disproportionately affected by cardiovascular complications. To address these uncertainties, researchers conducted a massive longitudinal analysis to determine how ethnicity correlates with the quality of care received during HF hospitalization and subsequent long-term survival in a system where financial barriers to care are largely removed.
Study Design and Methodology
The study, published in the Journal of the American College of Cardiology (JACC), utilized a comprehensive dataset from the National Heart Failure Audit (NHFA) in England, linked with National Health Service Hospital Episode Statistics and the Office for National Statistics death register. The study period spanned from 2018 to 2023, capturing data from nearly a quarter of a million patients.
The cohort included 239,890 patients hospitalized with acute heart failure. These patients were categorized into four primary groups: White (215,800), Black (6,610), Asian (12,940), and Mixed/Other (4,540). The researchers tracked several key metrics, including clinical characteristics at admission, the use of guideline-recommended therapies at discharge, and all-cause mortality over a median follow-up period of 68 weeks.
Key Findings: Demographics and Comorbidity Profiles
One of the most striking initial findings was the age gap at the time of presentation. White patients were significantly older, with a median age of 81 years, compared to 75 years for Black and Mixed-ethnicity patients, and 77 years for Asian patients. This age disparity is clinically significant, as it suggests that heart failure may manifest earlier in minority populations or that the survivorship to older ages in the White population leads to a different phenotypic presentation of the disease.
Comorbidity burdens also varied. While all groups had a median of three comorbidities, Asian patients presented with the highest overall number of concurrent conditions, including significantly higher rates of diabetes and chronic kidney disease. Despite these higher comorbidity levels in some groups, the prevalence of heart failure with reduced ejection fraction (HFrEF)—the phenotype most responsive to pharmacological intervention—was consistent at approximately 50% across all ethnic groups.
Quality of Care and Pharmacological Management
The core of the study’s findings lies in the quality of care provided at the point of discharge. For patients with HFrEF, the research revealed a surprising trend: White patients were the least likely to be discharged on the full suite of guideline-recommended therapies, including ACE inhibitors, ARBs, or ARNIs; beta-blockers; and mineralocorticoid receptor antagonists (MRAs).
Conversely, Black and Asian patients were more likely to receive these life-prolonging medications. This higher adherence to clinical guidelines among minority groups was strongly associated with access to specialist heart failure teams during their hospital stay. The data suggests that when specialist teams are involved, the implementation of evidence-based medicine is more robust, and in this cohort, minority patients were more frequently managed by these specialists.
Mortality Outcomes: A Reversal of Expected Trends
The mortality data provided the most compelling evidence for the “specialist care effect.” During the follow-up period, 57% of White patients died, compared to 43% of Black patients and 48% of Asian patients. Most deaths (approximately 90%) were attributed to cardiovascular or respiratory causes.
Crucially, after adjusting for age (to account for the fact that White patients were older), sex, socioeconomic status, and disease severity, the mortality risk remained significantly lower for ethnic minorities compared to White patients:
- Black patients: Hazard Ratio (HR) 0.81 (95% CI: 0.78-0.84)
- Asian patients: HR 0.77 (95% CI: 0.75-0.79)
- Mixed/Other groups: HR 0.72 (95% CI: 0.69-0.75)
These findings indicate a 19% to 28% lower risk of death for non-White patients compared to their White counterparts when treated within the same universal healthcare framework.
Expert Commentary and Clinical Implications
The results of this study challenge the narrative that ethnic minority status is inherently linked to poorer medical outcomes in Western nations. Instead, they suggest that the healthcare delivery model plays a transformative role. In a system like the NHS, where specialist heart failure services are integrated into the hospital journey, the “gap” in care can be closed.
However, the study also raises questions about why White patients—particularly the very elderly—received less intensive pharmacological management. It is possible that clinical “nihilism” regarding the very old (median age 81), concerns over polypharmacy, or higher rates of frailty in the White cohort led clinicians to be more cautious with aggressive GDMT. Furthermore, the concentration of ethnic minority populations in major urban centers may provide them with better proximity to high-volume tertiary centers with dedicated heart failure specialists.
From a biological perspective, some researchers have previously suggested that certain ethnic groups may respond differently to HF medications. However, this study suggests that the primary driver of the survival advantage was simply the higher rate of guideline-concordant prescribing, rather than a hidden biological factor.
Conclusions
The analysis by Cannata et al. provides a powerful testament to the efficacy of specialist-led care within a universal health system. It demonstrates that when pharmacological management is optimized, ethnic minority patients with heart failure can achieve excellent long-term outcomes, even surpassing those of the majority population. For clinicians and policy makers, the message is clear: the focus must remain on ensuring equitable access to specialist heart failure teams and the rigorous application of guideline-directed medical therapy for all patients, regardless of age or ethnicity.
References
- Cannata A, Mizani MA, Bromage DI, et al. Ethnicity and Heart Failure Outcomes in England: Role of Specialist Care in a Universal Health System. J Am Coll Cardiol. 2026;87(10):1235-1256.
- McDonagh TA, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599-3726.
- Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. J Am Coll Cardiol. 2022;79(17):e263-e421.
